Regeneron Pharmaceuticals ( NASDAQ:REGN – Get Rating ) had its price objective lifted by analysts at BMO Capital Markets from $1,001.00 to $1,025.00 in a research note issued on Tuesday, The Fly reports. The brokerage presently has an 'outperform' rating on the biopharmaceutical company's stock. BMO Capital Markets' price objective points to a potential upside of 39.19% from the stock's current price. Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada lifted their target price on Regeneron Pharmaceuticals from $787.

https://www.dailypolitical.com/2023/03/16/regeneron-pharmaceuticals-nasdaqregn-pt-raised-to-1025-00-at-bmo-capital-markets.html

#dailypolitical